ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016

Redwood City, CA, April 20, 2016 —ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced that two abstracts with clinical data on the Company’s lead investigational drug AM0010 (PEGylated Interleukin-10) as monotherapy and in combination with an anti-PD-1 monoclonal antibody for the treatment of advanced malignancies will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016 in Chicago, Illinois.

Abstract Title: Clinical activity and safety of PEGylated human IL-10 (AM0010) in combination with anti-PD1 (Abstract #3018, Poster Board #340)
Presenter: Aung Naing, M.D., Associate Professor, Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas
Session: Developmental Therapeutics - Immunotherapy
Poster: Sunday, June 5, 2016, 8:00 – 11:30 am Central Time
Poster Discussion: Sunday, June 5, 2016, 4:45 pm – 6:00 pm Central Time

Abstract Title: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer (Abstract #3082, Poster Board #404)
Presenter: Kyriakos Papadopoulos, M.D., Senior Clinical Investigator at START Center for Cancer Care, San Antonio, Texas
Session: Developmental Therapeutics - Immunotherapy
Poster: Sunday, June 5, 2016, 8:00 – 11:30 am Central Time

About ARMO BioSciences

Founded in 2012, ARMO BioSciences is a clinical-stage company developing immunotherapies focused on multiple difficult-to-treat oncology indications. The company’s lead immunotherapy AM0010, a PEGylated form of recombinant human IL-10, primes the tumor micro-environment for immune-mediated therapies and has demonstrated durable clinical responses in several types of cancer, as both a single agent and in combination with standard-of-care chemotherapy or anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibodies. ARMO plans to initiate the first of several registration-enabling phase 2-3 studies for AM0010 in solid tumors. The company also has a robust pipeline of therapeutic cytokines and an anti-PD-1 checkpoint inhibitor.

For more information, please visit www.armobio.com

Contact

ARMO BioSciences
Scott Ogg, PhD
Vice President Corporate Development and Operations
+1-650-779-5075